Abstract
This study investigated effects of glucagon-likepeptide-1(7-36)amide (GLP-1) on gastric emptying, smallintestinal transit, and contractility of smooth musclestrips in rats. GLP-1 at doses of 10 and 20 pmol/kg/min administered intravenouslydose-dependently retarded transit of the small intestine(P < 0.001), while only the higher dose of 20pmol/kg/min retarded gastric emptying (P < 0.01).GLP-1 at concentrations up to 10-4 M didnot affect the basal tone or contractility of thegastrointestinal muscle strips that were stimulated withelectric field stimulation or acetylcholine. Our resultsdemonstrate that small intestinal transit seems moresensitive than gastric emptying to inhibition by GLP-1at physiologic levels in plasma. Furthermore, thisinhibition appears to be mediated through centralmechanisms rather than through peripheral actions. Thus,GLP-1 is suggested to inhibit gastric emptying and smallintestinal transit through an indirect effect viacentral or enteric nervous mechanisms.
Similar content being viewed by others
REFERENCES
Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF: Preproglucagon gene expression in pancreas and intestine diversifies at the level of posttranslational processing. J Biol Chem 261:11880 - 11886, 1986
Ørskov C, Holst JJ, Knuhtsen S, Baldisse ra FGA, Poulsen SS, Nielsen OV: Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from the pig small intestine, but not pancre as. Endocrinology 119:1467 - 1475, 1986
Ørskov C, Holst JJ, Poulsen SS, Kirkegaard P: Pancre atic and intestinal processing of proglucagon in man. Diabe tologia 30:874 - 881, 1987
Holst JJ, Ørskov C, Nielsen OV, Schwartz TW: Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 211:169 - 174, 1987
Holst JJ: Enteroglucagon. Adv Metab Dis 11:392 - 419, 1988
Kreymann B, Ghatei MA, Williams G, Bloom SR: Glucagonlike peptide-1 7-36: A physiological incretin in man. Lancet 2:1300 - 1303, 1987
Mojsov S, Weir GC, Habene r JF: Insulinotropin: Glucagonlike peptide-I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin rele ase in the perfused rat pancreas. J Clin Invest 79:616 - 619, 1987
Ø rskov C, Holst JJ, Nielsen OV: Effect of truncated glucagonlikepeptide-1 (proglucagon-(78 - 107) amide ) on endocrine secretion from pig pancreas, antrum, and non-antral stomach. Endocrinology 123:2009–2013, 1988
Wettergre n A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ: Truncated GLP-1 (proglucagon 78 - 107-mide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38:665± 673, 1993
Gutniak MK, Juntti-Berggre n L, Hellströ m PM, Guenifi A, Holst JJ, Efendic S: Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas. Diabetes Care 19:857 - 863, 1996
Ø rskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ: Tissue and plasma concentrations of amidated and glycine extended glucagon-like peptide-1 in humans. Diabetes 43:535 -539, 1994
Deacon CF, Johnsen AH, Holst JJ: Degradation of glucagonlike peptide-1 by human plasma in vitroyields an N-terminally truncated peptide that is a major endogenous me tabolite in vivo. J Clin Endocrinol Metab 80:952 - 957, 1995
Hjelm M, de Verdier C: A methodological study of the enzymatic determination of glucose in blood. Scand J Clin Lab Invest 15:415 - 428, 1963
Hellström PM, Nylander G, Rosell PM: Effects of neurotensin on the transit of gastrointe stinal contents in the rat. Acta Physiol Scand 115:239 - 243, 1982
Miller MS, Galligan JJ, Burks TF: Accurate measurement of intestinal transit in the rat. J Pharmacol Methods 6:211 - 217, 1981
Hellstrøm PM, Johansson C: Neuropeptide Y inhibits the migrating myoelectric complex and delays small intestinal transit in man. J Gastrointest Motil 1:35 - 41, 1989
Tolessa T, Gutniak M, Efendic S, Hellstr÷m PM: Inhibition of migrating myoelectric complex by glucagon-like peptide-1, but not glucagon, is partially mediated through nitric oxide and partially direct. Neurogastroenterol Motil 8:194A, 1996
Giralt M, Guo X, Vergara P: Glucagon-like-peptide-1 induces inhibitory actions in the gastrointestinal tract of the rat. Neurogastroenterol Motil 8:173A, 1996
Wheeler MB, Lu M, Dillon JS, Leng XH, Chen C, Boyd AE: Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase C. Endocrinology 133:57 - 62, 1993
Wettergre n A, Petersen H, Ørskov C, Christiansen J, Sheikh SP, Holst JJ: Glucagon-like peptide-1 (GLP-1) 7-36 amide and peptide YY from the L-cell in the ileal mucosa are potent inhibitors of vagally induced gastric acid in man. Scand JGastroenterol 29:501 - 505, 1994
Ørskov C, Wettergren A, Poulsen SDS, Holst JJ: Is the effect of glucagon-like peptide-1 on gastric emptying centrally mediated? Diabetologia 38:A39, 1995
Wei Y, Mojsov S: Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 358:219 - 224, 1995
Ørskov C, Poulsen SS, Møller M, Holst JJ: Glucagon-like peptide-1 receptors in the subfornical organ and the area postrema are acce ssible to circulating glucagon-like peptide-1. Diabetes 45:832 - 835, 1996
d'Alessio DA, Fujimoto WY, Ensinck JW: Effects of glucagonlike peptide I-(7-36) on re lease of insulin, glucagon, and somatostatin by rat pancreatic islet cell monolayer cultures. Diabetes 38:1534 - 1538, 1989
Ishii M, Nakamura T, Kasai F, Onuma T, Baba T, Takebe K: Altered postprandial insulin requirement in IDDM patients with gastroparesis. Diabetes Care 17:901 - 903, 1994
Krarup T, Schwartz TW, Hilsted J, Madsbad S, Overlaege O, Sestoft L: Impaired response of pancreatic polypeptide to hypoglycaemia: an early sign of autonomic neuropathy in diabetics. Br Med J 2:1544 - 1546, 1979
Cryer PE: Hypoglycaemia-associated autonomic failure. InHypoglycaemia and Diabetes. BM Frier, M Fisher (eds). London, Arnold, 1993, pp 275 - 283
Horowitz M, Dent J: Disordered gastric emptying: me chanical basis, assessment and treatment. Bailliere's Clin Gastroente rol 5:371 - 407, 1991
Kreymann B, Ghatei MA, Schusdziarra V, Bloom SR, Classen M: Does the incretin effect exist for GIP or GLP-1 7-36 amide at physiological glucose concentrations in man? Digestion 46( suppl 1):59, 1990
Brown JC, Dryburgh JR, Ross SA, Dupré J: Identification and actions of gastric inhibitory polypeptide. Recent Prog Horm Res 31:487 - 532, 1975
Schang JC, Kelly KA: Inhibition of canine interdigestive proximal gastric motility by cholecystokinin octapeptide. Am J Physiol 240:G217 - G220, 1981
Szecowka J, Lins PE, Efendic S: Effects of cholecystokinin, gastric inhibitory polypeptide, and secre tin on insulin and glucagon secretion in rats. Endocrinology 110:1268 - 1272, 1982
Rushakoff RJ, Goldfine ID, Carter JD, Liddle RA: Physiological concentrations of cholecystokinin stimulate amino acid release in humans. J Clin Endocrinol Metab 65:395 - 401, 1987
Bueno L, Ruckebusch Y: Insulin and jejunal electrical activity in dogs and sheep. Am J Physiol 230:G1538 - G1544, 1977
Shima K, Hirota M, Ohboshi C: Effect of glucagon-like peptide-1 on insulin secretion. Regul Pept 22:245 - 252, 1988
Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, Kono N, Tarui S: Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide. Diabetes 38:902-905, 1989
Gefe l D, Hendrick GK, Mojsov S, Habener JF, Weir GC: Glucagon-like peptide-I analogs: effects on insulin secretion and adenosine 39, 59-monophosphate formation. Endocrinology 126:2164 - 2168, 1990
Rights and permissions
About this article
Cite this article
Tolessa, T., Gutniak, M., Holst, J.J. et al. Glucagon-like Peptide-1 Retards Gastric Emptying and Small Bowel Transit in the Rat (Effect Mediated Through Central or Enteric Nervous Mechanisms). Dig Dis Sci 43, 2284–2290 (1998). https://doi.org/10.1023/A:1026678925120
Issue Date:
DOI: https://doi.org/10.1023/A:1026678925120